Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Department of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran.
J Stud Alcohol Drugs. 2024 Sep;85(5):704-712. doi: 10.15288/jsad.23-00377. Epub 2024 Mar 22.
Opioids are potent pain relievers for managing severe pain. However, their effectiveness is hindered by tolerance, which causes the need for higher doses and leads to adverse effects. In a previous study, we found that prolonged use of apelin, similar to opioids, results in a tolerance to its analgesic effects. It remains unclear whether there is a cross-tolerance between morphine and apelin, meaning if the analgesic effects of one can reduce the effectiveness of the other.
The tail-flick test was used to assess the nociceptive threshold. All experiments were carried out on 63 male Wistar rats, which received intrathecal apelin (3 μg/rat) or morphine (15 μg/rat) for 7 days. To determine cross-tolerance between the analgesic effect of morphine and apelin, the analgesic property of apelin or morphine was assessed in chronic morphine- or apelin-treated groups, respectively. To determine the role of apelin and opioid receptors signaling on the development of analgesic cross-tolerance, F13-A and naloxone, as apelin and opioid receptor antagonists, were injected simultaneously with morphine or apelin. At the end of the tests, the expression levels of apelin and μ-opioid receptors were evaluated by western blotting.
The data indicated that chronic apelin or morphine use produced tolerance to the antinociceptive effects of each other. F13-A and naloxone could inhibit the induction of such cross-tolerance. The molecular data showed that there was a significant downregulation of apelin receptors in chronic morphine-treated rats and vice versa.
Chronic administration of apelin or morphine induces analgesic cross-tolerance that may, in part, be mediated through receptor interactions and downregulation. The demonstrated efficacy of F13-A in these experiments highlights its potential as a novel target for improving pain management through the inhibition of the apelin/APJ signaling pathway, meriting further investigation.
阿片类药物是治疗严重疼痛的强效止痛药。然而,它们的有效性受到耐受性的阻碍,这导致需要更高的剂量,并导致不良反应。在之前的一项研究中,我们发现阿皮素的长期使用(类似于阿片类药物)导致其镇痛作用的耐受性。目前尚不清楚吗啡和阿皮素之间是否存在交叉耐受,也就是说,一种药物的镇痛效果是否会降低另一种药物的疗效。
采用尾部闪烁测试评估痛觉阈值。所有实验均在 63 只雄性 Wistar 大鼠上进行,这些大鼠接受鞘内阿皮素(3μg/只)或吗啡(15μg/只)治疗 7 天。为了确定吗啡和阿皮素镇痛作用之间的交叉耐受,分别在慢性吗啡或阿皮素处理组中评估阿皮素或吗啡的镇痛特性。为了确定阿皮素和阿片受体信号在镇痛交叉耐受发展中的作用,同时注射 F13-A 和纳洛酮作为阿皮素和阿片受体拮抗剂与吗啡或阿皮素一起使用。在测试结束时,通过 Western 印迹评估阿皮素和μ-阿片受体的表达水平。
数据表明,慢性阿皮素或吗啡使用导致彼此的抗伤害作用产生耐受性。F13-A 和纳洛酮可以抑制这种交叉耐受的诱导。分子数据显示,慢性吗啡处理的大鼠中阿皮素受体的表达显著下调,反之亦然。
慢性给予阿皮素或吗啡会诱导镇痛交叉耐受,部分可能通过受体相互作用和下调介导。在这些实验中 F13-A 的有效作用突出了其作为通过抑制阿皮素/APJ 信号通路改善疼痛管理的潜在新靶点的潜力,值得进一步研究。